Brain connectivity tracks effects of chemotherapy separately from behavioral measures.


Journal

NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070

Informations de publication

Date de publication:
2019
Historique:
received: 13 08 2018
revised: 06 12 2018
accepted: 03 01 2019
pubmed: 16 1 2019
medline: 4 1 2020
entrez: 16 1 2019
Statut: ppublish

Résumé

Several studies in cancer research have suggested that cognitive dysfunction following chemotherapy, referred to in lay terms as "chemobrain", is a serious problem. At present, the changes in integrative brain function that underlie such dysfunction remain poorly understood. Recent developments in neuroimaging suggest that patterns of functional connectivity can provide a broadly applicable neuromarker of cognitive performance and other psychometric measures. The current study used multivariate analysis methods to identify patterns of disruption in resting state functional connectivity of the brain due to chemotherapy and the degree to which the disruptions can be linked to behavioral measures of distress and cognitive performance. Sixty two women (22 healthy control, 18 patients treated with adjuvant chemotherapy, and 22 treated without chemotherapy) were evaluated with neurocognitive measures followed by self-report questionnaires and open eyes resting-state fMRI scanning at three time points: diagnosis (M0, pre-adjuvant treatment), 1 month (M1), and 7 months (M7) after treatment. The results indicated deficits in cognitive health of breast cancer patients immediately after chemotherapy that improved over time. This psychological trajectory was paralleled by a disruption and later recovery of resting-state functional connectivity, mostly in the parietal and frontal brain regions. Mediation analysis showed that the functional connectivity alteration pattern is a separable treatment symptom from the decreased cognitive health. Current study indicates that more targeted support for patients should be developed to ameliorate these multi-faceted side effects of chemotherapy treatment on neural functioning and cognitive health.

Identifiants

pubmed: 30642760
pii: S2213-1582(19)30004-X
doi: 10.1016/j.nicl.2019.101654
pmc: PMC6412071
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101654

Subventions

Organisme : NINR NIH HHS
ID : R01 NR010939
Pays : United States

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Omid Kardan (O)

University of Chicago, United States. Electronic address: okardan@uchicago.edu.

Patricia A Reuter-Lorenz (PA)

University of Michigan, United States.

Scott Peltier (S)

University of Michigan, United States.

Nathan W Churchill (NW)

St. Michael's Hospital, Canada.

Bratislav Misic (B)

Montreal Neurological Institute, Canada.

Mary K Askren (MK)

University of Washington, United States.

Mi Sook Jung (MS)

Chungnam National University, South Korea.

Bernadine Cimprich (B)

University of Michigan, United States.

Marc G Berman (MG)

University of Chicago, United States. Electronic address: bermanm@uchicago.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH